IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) - IMVT-1401-3201

Immunovant Sciences GmbH0 个研究点目标入组 100 人开始时间: 2024年5月31日最近更新: 2024年8月21日

研究概览

暂无简介。

•Are =18 years of age at screening., Have a clinical diagnosis of TED associated with active, moderate to severe TED with a CAS =4 in either eye, and clinical evidence of worsened proptosis with: - Proptosis = 18 mm and/or - Proptosis = 3 mm increase from participant's baseline (prior to diagnosis of TED), as estimated by the Investigator/assessor, Have moderate to severe active TED, as defined by European Group on Graves' Orbitopathy (EUGOGO) guidelines., Have onset of active TED within 12 months prior to screening., Have documented evidence of detectable anti-TSHR-Ab at screening., Are not expected to require immediate surgical intervention and are not planning corrective surgery/irradiation or medical therapy for TED during the course of the study., Are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism.

•Have decreased best corrected visual acuity due to optic neuropathy., Have at least a 2-point decrease in CAS or =2 mm decrease in proptosis between screening and Baseline assessments in either eye., Have used any steroid (intravenous or oral) for the treatment of TED or other conditions within 4 weeks prior to screening., Have used any steroid (Intravenous or oral) with a cumulative dose equivalent to = 1 g of methylprednisolone for the treatment of TED., Have known autoimmune disease other than TED, that, in the opinion of the Investigator, would interfere with the course and conduct of the study., Had previous orbital irradiation or surgery for TED.

发起方